Identification | More | [Name]
1-Boc-4-(2-hydroxyethyl)piperidine | [CAS]
89151-44-0 | [Synonyms]
1-BOC-4-(2-HYDROXYETHYL)PIPERIDINE 4-(2-HYDROXYETHYL)PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER BOC-2-(4-PIPERIDYL)ETHANOL N-BOC-4-PIPERIDINEETHANOL N-(TERT-BUTOXYCARBONYL)-4-PIPERIDINEETHANOL 4-(2-Hydroxyethyl)piperidine, N-BOC protected 1-BOC-4-PIPERIDINE EHTANOL 1-PIPERIDINECARBOXYLIC ACID, 4-(2-HYDROXYETHYL)-1, N-TERT-BUTOXYCARBONYL-4-PIPERIDINEETHANOL 95+% tert-butyl 4-(2-hydroxyethyl)piperidine-1-carboxylate | [EINECS(EC#)]
692-472-5 | [Molecular Formula]
C12H23NO3 | [MDL Number]
MFCD03427086 | [Molecular Weight]
229.32 | [MOL File]
89151-44-0.mol |
Chemical Properties | Back Directory | [Boiling point ]
120-150 °C/0.5 mmHg (lit.) | [density ]
1.043 g/mL at 25 °C(lit.)
| [refractive index ]
n20/D 1.4730(lit.)
| [Fp ]
>230 °F
| [storage temp. ]
Keep in dark place,Sealed in dry,Room Temperature | [form ]
viscous liquid | [pka]
15.10±0.10(Predicted) | [color ]
Colourless to light yellow | [InChI]
InChI=1S/C12H23NO3/c1-12(2,3)16-11(15)13-7-4-10(5-8-13)6-9-14/h10,14H,4-9H2,1-3H3 | [InChIKey]
YBNJZIDYXCGAPX-UHFFFAOYSA-N | [SMILES]
N1(C(OC(C)(C)C)=O)CCC(CCO)CC1 | [CAS DataBase Reference]
89151-44-0(CAS DataBase Reference) |
Hazard Information | Back Directory | [Uses]
N-BOC-4-piperidine-β-ethanol is used to prepare anilinoquinazoline VEGF receptor tyrosine kinase inhibitors with antitumor activities. It is also used to synthesize 1,3,4-trisubstituted pyrrolidine CCR5 receptor antagonists with antiviral activities. | [Synthesis]
General procedure for the synthesis of N-Boc-4-piperidine ethanol from tert-butyl 4-(2-ethoxy-2-oxo-substituted)piperidine-1-carboxylate: first, the above product (639 mg, 2.4 mmol) was dissolved in 6 mL of methanol, protected by argon, replaced three times with hydrogen and reacted overnight in a hydrogenation unit (4 atm H2). Upon completion of the reaction, the reaction solution was filtered through diatomaceous earth and washed with ethyl acetate. The filtrate was concentrated and purified by column chromatography to give a white solid product (722 mg, 100% yield). Subsequently, the above product (506 mg, 1.9 mmol) was dissolved in 10 mL of ether, cooled to -20 °C, and hydrogenated diisobutylaluminum (1.0 M, 5 mL, 5 mmol) was slowly added, and the reaction was carried out for 10 min until the raw material completely disappeared. The reaction mixture was poured into saturated potassium sodium tartrate solution and stirred at room temperature for 3 hours until clarified. The aqueous phase was extracted three times with ether, the organic phases were combined, washed with saturated NaCl solution and dried over anhydrous Na2SO4. After concentration, the product was purified by column chromatography to give a white solid product (368 mg, 86% yield). | [References]
[1] Patent: CN102952072, 2016, B. Location in patent: Paragraph 0110-0111 [2] Bioorganic and Medicinal Chemistry Letters, 2003, vol. 13, # 13, p. 2167 - 2172 [3] Patent: US2012/71461, 2012, A1 [4] Patent: CN107793408, 2018, A [5] Patent: WO2018/68297, 2018, A1 |
|
|